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Immunoproteomics: The Key to Discovery of New Vaccine Antigens
Against Bacterial Respiratory Infections
Ruth Dennehy and Siobhán McClean*
Centre of Microbial Host Interactions, Centre of Applied Science for Health, Institute of Technology Tallaght, Old
Blessington Road, Dublin 24, Ireland
Abstract: The increase in antibiotic resistance and the shortage of new antimicrobials to prevent difficult bacterial infections underlines the importance of prophylactic therapies to prevent infection by bacterial pathogens. Vaccination has reduced the incidence of many serious diseases, including respiratory bacterial infections. However, there are many pathogens for which no vaccine is available and some vaccines are not effective among all age groups or among immunocompromised individuals. Immunoproteomics is a powerful technique which has been used to identify potential vaccine candidates to protect against pathogenic bacteria. The combination of proteomics with the detection of immunoreactive antigens using serum highlights immunogenic proteins that are expressed during infection. This is particularly useful when
patient serum is used as the antigens that promote a humoral response during human infection are identified. This review
outlines examples of vaccine candidates that have been identified using immunoproteomics and have successfully protected animals against challenge when tested in immunisation studies. Many immunoreactive proteins are common to several unrelated pathogens, however some of these are not always protective in animal immunisation and challenge studies.
Furthermore, examples of well-established immunogens, including Bordetella pertussis antigen FHA were not detected in
immunoproteomics studies, indicating that this technology may underrepresent the immunoreactive proteins in a pathogen. Although only one step in the pathway towards an efficacious approved vaccine, immunoproteomics is an important
technology in the identification of novel vaccine antigens.

Keywords: Antigens, immunoproteomics, immunoreactive proteins, respiratory disease, vaccine, virulence.
INTRODUCTION
The value of vaccination as a means of combating lifethreatening and chronic infectious diseases is well established. Many diseases which previously contributed to mortality are now prevented by vaccination. However, according
to the WHO, about 1.5 million of deaths among children
under five in 2008 were caused by vaccine preventable diseases. In addition many approved vaccines are more effective in young children than in adolescents and adults. Given
that infectious diseases are still the leading global cause of
morbidity and mortality and when considered in the context
of both the rise in antimicrobial resistance and the lack of
novel effective antibiotics in the drug development pipeline
[1], the need for more efficacious vaccines for bacterial
pathogens cannot be underestimated.
There are several bacterial cell components incorporated
into subunit vaccines, LPS, glycoconjugated vaccines, DNA
vaccines, protein vaccines, which in addition to live attenuated vaccines and whole killed cell vaccines stimulate the
host immune response in a variety of ways. Vaccine studies
have often focussed on lipopolysaccharide (LPS) due to its
potent stimulation of the immune response; however the antigenic diversity of the O-antigen component of LPS within
*Address correspondence to this author at the Centre of Microbial Host
Interactions, Centre of Applied Science for Health, Institute of Technology
Tallaght, Old Blessington Road, Dublin 24, Ireland; Tel: +3531-404 2794;
Email: Siobhan.mcclean@ittdublin.ie
1875-5550/12 $58.00+.00

species has limited the potential of LPS as potential vaccine
antigens, for example P. aeruginosa LPS [2]. Many approved vaccines are glycoconjugate in nature (e.g. vaccines
for Neisseria meningitidis and Streptococcus pneumoniae)
and have proved effective against certain serogroups of
pathogens; but they tend to suffer from the same issues with
variability across strains. In addition, serotype switching and
serotype replacement may undermine their effectiveness in
the future [3]. Proteins are often more conserved across bacterial strains and have more potential to protect against several strains of the same bacterial species.
Investigation and harnessing of the host-pathogen response are beneficial to two separate but essential aspects to
vaccine development. Exploitation of the human humoral
response by determining immunogenic bacterial protein using sera from vaccinated, colonised or recovering individuals
has played an important part in identifying novel vaccine
antigens. Identification of novel antigens is only part of the
process of vaccine development, therefore examination of
the host response in adults and in human volunteers at the
cellular and humoral response level is also essential in the
development of more efficacious vaccines. Protection against
certain intracellular pathogens requires a strong cellmediated immune response driven by polarisation towards a
Th1 response; while other extracellular pathogens are best
protected by a Th2 response which promotes antibody production and antibody-mediated cell killing [4]. Indeed
knowledge of the interactions between pathogens and host
© 2012 Bentham Science Publishers
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cells in vitro is also critical, where the bacterial components
that attach to host cells are investigated and elucidated. This
review will focus on a number of examples of the exploitation of the host response in the identification of novel antigens and in the development of identified vaccine antigens as
prophylactic therapies against respiratory bacterial diseases.
EXPLOITING THE MICROBIAL–HOST RESPONSE
TO IDENTIFY NEW ANTIGENS
Reno Rappuoli and co-workers pioneered the use of a
genomics approach to identify novel antigens against Neisseria meningitidis serogroup B using reverse vaccinology, in
the late 1990s. They sequenced the genome of the pathogen,
identified proteins which were likely to be surface associated, expressed these in Escherichia coli and administered
the 350 proteins to mice to identify those that were immunogenic [5]. The sequencing step of the process took 18 months
at the time. The development of genomics since then has
meant a rapid expansion in the capabilities to identify new
antigens. Over 2,800 bacterial genomes have been completely sequenced at time of writing, a figure which is increasing week on week (NCBI Microbial genomes:
www.ncbi.nlm.nih.gov/genome). This vast bank of information combined with the advances in proteomics, including,
the relatively reproducibility and ease of preparing 2-D gels
has meant a rapid increase in proteomic analysis of bacterial
pathogens which has given insights into mechanisms of bacterial virulence and pathogenesis, adaptation during chronic
colonisation and host response. The natural step up to immunoproteomics, whereby 2-D blots are probed with host
serum following infection or immunisation has greatly enhanced the identification of potential vaccine candidates, by
enabling the discovery of novel proteins that stimulate the
humoral host immune system. A key advantage of this approach is that final expressed bacterial proteins are used in
the analysis, which have been completely processed and
post-translationally modified by the pathogen. Several
groups have used this method to discover potential vaccine
candidates with varying degrees of success. Different sera
have been used in these types of studies which range from
using colonised patient sera, convalescent sera, or sera from
challenged mice or rabbits. Furthermore, the majority of
immunoproteomic studies have focussed on cell surface proteins or outer membrane proteins as this subgroup of bacterial proteins represent the interface for host pathogen interactions and regularly include adhesins. Other groups have examined secreted proteins as they are also primary antigen
targets of the host immune response and include many virulence factors. Collectively, their exposure to the host immune system marks these pools of proteins as a rich source
of vaccine candidates.
Streptococcus Pneumoniae
Streptococcus pneumoniae is a Gram positive bacterium
that is a leading cause of bacterial pneumonia, meningitis
and pneumococcal septicaemia. It accounts for 20 to 50% of
community acquired pneumonia cases and is the cause of
over 820,000 deaths each year in children under five [6]. The
seven-valent glycoconjugate pneumococcal vaccine Prevnar
7 has reduced the incidence of invasive pneumococcal disease in children and mortality from this disease; however, it
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is not optimal for protection in children under two or in immunocompromised patients [3]. Furthermore, there has been
serotype replacement and increased incidence of non-vaccine
serotypes, including the antimicrobially resistant serotype
19A, which now predominates in some countries [3]. Although the recently approved 10- and 13-valent vaccines
target more serotypes and prevent invasive disease in children, there are at least 92 serotypes. This means that identification of protein antigens which are more highly conserved
across the species than the capsular polysaccharides may
present more effective alternatives.
Immunoproteomics has been used to identify potential
immunogenic antigens in S. pneumoniae. Adults develop
antibodies to S. pneumoniae during asymptomatic carriage
and it has been shown that the antibody response is age dependent [7,8]. This increase in antibody response to S.
pneumoniae proteins which correlated with a reduction in
morbidity in children prompted Ling et al., to focus on antigens which showed increased immunogenicity with age of
the child [9]. Two-dimensional Western blotting of cell wall
fractions from S. pneumoniae probed with sera from healthy
children ranging in age from 18 to 42 months or with sera
from adults highlighted seventeen immunoreactive proteins.
Two of these, both metabolic enzymes, were equally protective against two genetically different strains in a mouse challenge model. While this indicates promise for the proteomic
approach to identify protective antigens, the protection obtained was only 36%. Another two antigens identified in this
study, 6-phosphogluconate dehydrogenase (6-PGD) and Glutamyl-tRNA synthase were subsequently shown to be involved in adhesion to A549 cells [10,11]. While both independently protected mice against a lethal challenge, the level
of protection was only marginally better than that observed
with GAPDH and Fructose-bis-phosphate aldolase. In the
case of 6-PGD, immunization also reduced lung and blood
colonisation levels by several fold. The latter antigen, glutamyl-tRNA synthase shows promise due its lack of a human
orthologue, the former protein has high homology to the human orthologue which could be detrimental to its development as a protective antigen [11].
A separate proteomic analysis of cell wall proteins identified proteins which were expressed across at least 40 S.
pneumoniae serotypes and during animal infection [12]. Five
proteins were evaluated in a mouse sepsis model, and although lung bacterial burdens were reduced following individual immunisations with two of the proteins, these did not
prolong the survival of mice. The poorer outcome in this
study, compared with that of Ling and co-workers, may be
due to the fact that immunogenic proteins were not necessarily selected for this study. More recently, immunoproteomic
analysis of the S. pneumoniae secretome also identified antigens which were shown to be immunogenic using immunised rabbit serum [13]. In total 54 proteins were detected, of
which only 23 were identified, including several proteins
which were known virulence factors, in addition to novel
proteins. These have the potential as diagnostic markers in
addition to vaccine candidates. Many of these immunogenic
proteins had been previously identified in other species and
in some cases by Ling et al., e.g., Enolase, ZmpB, serine
protease [9]. However, vaccine studies on these have not
been reported to date.
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Overall, the comparable survival rates following lethal
challenge (36 to 40%) for the four separate antigens described above and the lack of improved survival for others
may suggest that more knowledge of the specific protective
host response to S. pneumoniae is required to optimise further vaccine development. Indeed the finding that four distinct antigens showed very comparable survival rates may be
a feature of the animal model used. It is possible that mice
are not predictive of the immunological response to S. pneumoniae in humans. This is a key limitation of pre-clinical
vaccination studies that must be always considered. An example of this is highlighted below in the discussion on Bordetella pertussis immunoproteomics studies.
Burkholderia Pseudomallei and other Members of Genus
Burkholderia
Burkholderia pseudomallei, the causative agent of
melioidosis, is a Gram-negative, intracellular pathogen endemic in Southeast Asia and Northern Australia. The disease
is considerably variable in humans ranging from acute septicaemia, pneumonia to chronic or latent infection which can
persist and emerge decades later. The bacterium is intrinsically antibiotic resistant and has a mortality rate up to 50%;
however despite its significant morbidity and mortality, there
is currently no licensed vaccine against this infection. Harding et al., have used serum from convalescent patients to
probe 2-D blots of B. pseudomallei OMPs [14]. By biotinylation of the bacteria prior to OMP preparation, they were
able to focus solely on surface expressed proteins. They
identified nine surface proteins which were immunoreactive,
including elongation factor Tu (EF-Tu), polyribonucleotide
nucleotidyl transferase and two chaperones, GroEL and
DnaK. Among the biotinylated proteins identified were several that would be considered to be cytoplasmic. This highlights a common theme in proteomic analysis, that proteins
predicted to be cytoplasmic and without any signal peptide
are exposed at the bacterial surface [15]. A later study utilised rabbit serum to probe 2-D blots of membrane proteins
and again identified elongation factor Tu (EF-Tu) and DnaK
among the immunoreactive proteins of a less virulent related
species, B. thailandensis, which shares 94% identity at the
amino acid level with B. pseudomallei [16]. EF-Tu was
shown to be secreted in outer membrane vesicles (OMVs)
which are shed from B. pseudomallei during in vitro growth.
Mucosal immunisation of mice with EF-Tu resulted in the
generation of antigen specific IgG and IgA, polarised Th1
immune response and significantly reduced the bacterial
burden in the lungs following a lethal challenge with B. thailandensis. OMVs are gaining momentum as a potential vaccine platform [17,18]. These are engineered proteoliposomes
which incorporate the vaccine antigen, adjuvant in a particulate carrier. In a later study sub-cutaneous immunisation of
mice with purified B. pseudomallei OMVs resulted in protection of 60% of mice against a lethal challenge with high
OMV-specific titres, together with T-cell responses and humoral responses which were suggestive of a Th1 cellmediated immunity [19]. It was not stated whether these purified OMVs contained EF-Tu or what their antigenic composition was.
Immunoscreening of a lambda genomic library with
pooled patient serum represents an alternative way of identi-
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fying immunoreactive antigens in B. pseudomallei [20]. This
functional genomic approach allowed the screening of 5760
open reading frames which were then used to genetically
immunise mice. Three clones were selected from an initial
screen of 14 serum reactive phagemids, based on their strong
reactivity. Serological evaluation of 74 patients showed that
94% of patients were seropositive for one of these proteins,
OmpA. B. pseudomallei have several putative OmpA genes,
cloning of these resulted in 6 recombinant proteins. Two of
these were followed up, Omp3 which clustered with the
OmpA of E. coli and Klebsiella pneumonia OmpA following
multiple sequence alignment, and Omp7 which was closely
related to OmpA of Porphyromonas gingivalis [20]. Subsequent mouse immunisation with these resulted in 50% protection against a lethal challenge for two different recombinant OmpA proteins with the most reactivity with sera from
melioidosis patients [21]. When this pilot immunisation
study is considered together with the widespread seropositivity for OmpA among convalescent melioidosis patients, it
strongly suggest the potential for this antigen as one component of a future multi-valent vaccine against melioidosis.
Using a similar approach, Su et al., carried out a genomic
survey of B. pseudomallei, screening an expression library
with sera from melioidosis patients [22]. Among the 109
proteins identified from seropositive clones, one protein was
selected, OMP85, for later study, as it is a highly conserved
protein. Intraperitoneal immunisation of mice with this recombinant antigen resulted in 70% protection of mice over
15 days, as opposed to 10% in non-immunised mice in addition to significantly reduced bacterial load in lungs and
spleen [23].
Most recently, protein microarrays have been used to
identify immunoreactive proteins with plasma from recovered melioidosis patients or seropositive healthy individuals
[24]. Of the 27 antigens identified, seven were more strongly
recognised by plasma from recovered individuals over
healthy controls. These represented antigens which were
previously identified, and/or associated with virulence, including flagellin and flagellar hook associated protein,
OmpA and BipB, confirming the capacity for patient serum
to identify potential vaccine candidates. Although BipB was
previously shown not to prolong survival of challenged mice
[25], antibody levels against OmpA (one of the two OmpAs
which was also found to be protective by Hara et al. [21])
were 10-fold higher in patients that had only one episode of
melioidosis relative to those with recurrent disease, again
indicating that antibodies specific to this protein may be protective. Another closely related pathogen, Burkholderia cepacia is one of 17 closely related species that comprise the
Burkholderia cepacia complex [26]. This group of pathogens
are responsible for chronic lung infections in people with
cystic fibrosis and other immunocompromised individuals.
The secretory proteins of B. cepacia were analysed on 2-D
blots probed with serum from immunised mice [27]. One
protein in particular showed a 96% homology with a metalloprotease from a B. pseudomallei strain and it was suggested that this could cross-protect against both pathogens.
No in vivo challenge experiments were reported.
Overall, investigation of immunoreactive proteins in B.
pseudomallei using immunoproteomics or gene expression
libraries has already allowed the identification of vaccine
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candidates to protect against melioidosis, and further identification of additional antigens should allow the development
of a multivalent vaccine which will improve protection
against B. pseudomallei and eliminate bacterial persistence.
Taking both chronic infection and the intracellular lifestyle
of B. pseudomallei into consideration, it is evident that there
will be significant challenges in the development of an effective vaccine against this agent. A successful vaccine is likely
to need the induction of both humoral and cell-mediated immunity for the complete protection against this pathogen.
Neisseria meningitidis
N. meningitidis colonises the upper respiratory tract,
causing a mild respiratory infection, however in about 15%
of patients it invades. There are five serogroups of this Gram
negative pathogen which causes pneumonia, meningococcal
meningitis and septicemia. Glycoconjugate vaccines are
available which are effective against only four serogroups
and it is widely recognised that the disease can be prevented
by vaccination to induce antibody dependent complement
mediated bactericidal activity [28]. No vaccine exists for
serogroup B, which is responsible for over 30% of meningococcal disease in the US and up to 80% in Europe. In what
was the first application of reverse vaccinology, several serogroup B antigens were identified which resulted in high
titres of bactericidal antibodies, including, factor H binding
protein (fHbp) and Neisserial heparin binding antigen
(NHBA) [5]. Three highly immunogenic antigens (fHbp,
Neisseria adhesin (NadA) and NHBA were combined with
OMVs from an epidemic strain and are currently in phase III
clinical trials. In contrast to the studies on other pathogens, a
recent immunoproteomic analysis of Neisseria meningitidis
failed to identify potentially protective antigens, i.e antigens
which produced bactericidal antibodies when subsequently
tested in mice [29]. Sera from both acute and convalescent
patients were used to probe 2-D blots allowing the identification of 33 immunoreactive proteins. Interestingly many of
the proteins identified were also shown to be immunogenic
in other respiratory pathogens, e.g. GroEL, elongation factorTu, DnaK and cysteine synthase, but comparison of different
patient sera indicated that meningococcal patients have very
variable immune responses against a range of antigens.
When the recombinant proteins were expressed and administered to mice, all sera had significant protein-specific ELISA
titres, however none of these sera showed bactericidal activity. Protection of mice against challenge was not reported.
B. Pertussis
Bordetella pertussis is a Gram-negative bacterium responsible for the highly contagious respiratory infection,
whooping cough (pertussis), in humans. Pertussis vaccination exemplifies the benefits of vaccination and the issues
that arise when vaccine uptake wanes. The whole cell pertussis vaccine had a major impact on reducing childhood mortality when it was introduced in the 1940s, however, serious
side effects, including encephalitis, in a subgroup of vaccinated children led to its reduce uptake and consequent widespread outbreaks throughout the 1970. Introduction of the
acellular pertussis vaccine improved confidence and consequently uptake of the pertussis vaccination with the effect of
reducing the incidence among children for the next decade.
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However, while vaccination decreased the incidence of this
infection, there are reports of a resurgence of pertussis
among adults and adolescents in recent years, in developed
countries, despite good uptake of pertussis vaccination [30].
The current 5-component acellular vaccine administered in
combination with diphtheria and tetanus toxoids (DTaP) and
also combined with Haemophilus influenzae B and polio
antigens, contains five Bd. pertussis antigens. The antigens
include pertussis toxoid, filamentous hemagglutinin (FHA),
fimbriae 2 and 3 and pertactin. These antigens are all virulence factors and play a role in bacterial attachment (reviewed by Marzouqi et al. [31], and antibodies to these have
been identified in infected patients [32]. There is renewed
interest in improving pertussis vaccination which has led to a
number of immunoproteomics studies. These, however,
highlight some limitations of immunoproteomics. Two separate studies of Bd. pertussis surface proteins [33] and secretome [34] were carried out using mouse antisera from inactivated Bd. pertussis immunised mice as the primary antibody.
The surface immunoproteomes for two strains of Bd. pertussis were nearly identical. Among the 27 immunoreactive
proteins identified across both strains, pertactin which is a
component of the current approved pertussis vaccine, was
identified. Interestingly, although FHA is present in the surface proteome and is a highly immunogenic component of
acellular pertussis vaccines, it was not identified as an immunogenic protein among both lab strains examined in this
study [33]. This may be due to its very large molecular size
and consequent poor transfer to blotting membranes. Another study of immunoreactive proteins in Bd. pertussis analysed the serum of children that had been immunised with
the whole cell pertussis vaccine also identified pertactin
among the immunoreactive proteins, but neither FHA nor
pertussis toxin. Zhu et al., compared the murine immunoproteome with the human immunoproteome of Bd. pertussis and
found considerable differences in immunoreactivity [35].
Only four human immunoreactive proteins were detected
from immunised or infected mice and many human immunodominant antigens were not recognised by murine immune
sera. This clearly demonstrates that bacterial antigens may be
recognised differently by the murine and human immune
systems and may indicate that researchers should be cautious
when using murine antisera, or indeed antisera from other
species, in the identification of potential human vaccine antigens.
INVESTIGATING THE HOST RESPONSE TO ENHANCE THE EFFICACY OF IDENTIFIED ANTIGENS: DEVELOPMENT OF A P. AERUGINOSA
VACCINE
The identification of vaccine antigens by immunoproteomics or other immunomic analysis, although powerful
technologies, is only the first step in a long process to successful protective vaccine. Indeed, several immunogenic
proteins identified have failed to protect against challenge in
subsequent animal models (for example, BipB in B. pseudomallei [25] and GroEL and EF-Tu in N. meningitidis [29].
A full knowledge of the host response that is required for a
protective response in humans is essential in the development of an effective vaccine. The process involved is exemplified by the separate development of vaccine candidates
against P. aeruginosa. This is an opportunistic pathogen
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which colonises 80% of adults with the genetically inherited
disease cystic fibrosis, contributing to the mortality and morbidity of that disease. It is also responsible for a significant
proportion of ventilator associated pneumonias and colonises
and invades burn patients causing sepsis. P. aeruginosa
strains are characterised by intrinsic resistance to a range of
antimicrobial agents and antibiotics and have multiple
mechanisms of resistance which means that treatment is difficult. In susceptible populations, prevention of infection
would represent a better approach to therapy and indeed,
prevention of infection with P. aeruginosa is a major objective in the treatment of chronic obstructive pulmonary disease and cystic fibrosis. The development of protective vaccines to protect susceptible populations against this pathogen
spans several decades. The majority of the work has focussed on a limited number of antigens that showed promise
early in their development. The potential for outer membrane
protein OprF was first identified as a protective antigen as
early as 1984 [36] and its suitability confirmed when it was
demonstrated using a panel of monoclonal antibodies as being a conserved protein, with several conserved surface epitopes [37]. It was evaluated as a hybrid protein with another
conserved outer membrane protein OprI, which was also
antigenically cross-reactive against seventeen serogroups
[38]. This recombinant hybrid protein was subsequently
shown to protect immunosuppressed mice against P. aeruginosa challenge and was shown to be tolerated in human volunteers [39]. Antibodies against OprF have been shown to be
protective in burn and ocular models of P. aeruginosa infection [40,41], however, only partial responses have been
achieved in cystic fibrosis patients, so the recent focus of
development of this vaccine antigen has been in understanding the host response and optimising the adjuvant/ vaccine
administered to maximise the protective response. Investigation of the host response in chronically colonised CF patients
has suggested that a Th2 response correlated with infection,
while a Th1 cell response correlated with an improved outcome and may be more protective [42,43]. Bumann et al.,
have shown that a live vaccine constructed from a number of
attenuated Salmonella vaccine strains induced mucosal responses in human volunteers when administered orally or
nasally [44]. This phase I/II clinical trial on the OprF-OprI
conjugate vaccine demonstrated high levels of specific antibodies, including IgA at the bronchial surface and showed
that the nasal route was superior in terms of mucosal antibody response [44]. While this work towards an OprF-OprI
vaccine to protect children with CF against P. aeruginosa is
promising, a Phase III randomised control trial will be necessary to determine its efficacy and to demonstrate that antibody titres in this case, correspond to protection. An alternative immunisation approach using adoptive transfer of OprFpulsed dendritic cells as the vaccine in a mouse model
showed significant protection and clearance of P. aeruginosa
and activation of a Th1 response with a concomitant reduction in inflammatory cell recruitment. They also observed
protection against a mucoid strain which is generally associated with chronic colonisation of the CF lung, albeit a
slightly delayed response relative to the non-mucoid strain
[45].
Understanding the host pathogen interaction of these
vaccines will allow the development of future vaccines
which protect against different pathogens. Extensive host
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response studies have been carried out on the proteins involved in this OprF-OprI hybrid antigen. OprF has been
shown to involved in attachment of P. aeruginosa to host
cells [46] and is upregulated during chronic infection, in contrast to other virulence factors which are either lost or down
regulated [47]. OprF is involved a range of other virulence
characteristics in P. aeruginosa, including Type III secretion
system, production of virulence factors such as pyocyanin,
elastase and exotoxin A and adhesins [46], again illustrating
the potential of virulence factors and adhesins as protective
antigens. It has been suggested that OprF is a host immune
system sensor enabling P. aeruginosa to enhance virulence
when bacteria are in contact with the host [46].
Independently, another aspect of the P. aeruginosa attachment has been exploited, leading to the development of
flagellin and flagella-based vaccines which have been tested
in Phase III clinical trials. Most CF patients immunised developed high serum titres to flagella A and B and a significant reduction in the number of immunised patients that developed P. aeruginosa infection was observed among the
group of patients that received all four vaccinations [48].
Disappointingly, the study did not show a significant reduction in chronic infection in these patients, or an alteration in
the rate of decline in lung function. In a follow-on analysis
of the immune response to vaccination, Campodonico et al.,
showed that the polymeric flagella rather than monomeric
flagellin appeared to be superior for generating immunity to
P. aeruginosa. Antibodies to type a and b flagella were more
potent in mediating opsonic killing of P. aeruginosa and
mediating passive immunity in mice than serum raised to
flagellin. This was attributed to flagellin inducing high titres
of antibodies which could neutralise the innate immunity due
to TLR5 activation [49].
Combinations of both outer membrane proteins OprF and
OprI and flagellins have also been evaluated in a multimeric
fusion protein vaccine, in order to further optimise the protective host response by exploiting the ability of flagellin to
activate TLR-5 and act as an adjuvant as well as an antigen
[50]. Immunisation of mice with a combination of an OprF
epitope fused with OprI incorporated at the N-terminus of
the type A or type B flagellin resulted in high level of antibodies to OprF, flagellin and OprI. The Opr/flagellin recombinant proteins elicited high titres of IgG2a, in addition to
IgG1, although the response was biased towards a Th1 response. In addition, immunisation reduced the bacterial burden in mice challenged with non-mucoid P. aeruginosa
strains. One limitation of this study was that although antigen specific antibodies were able to activate complement,
complement-mediated killing was only effective against nonmucoid bacteria, being less effective against mucoid bacteria. The conversion of P. aeruginosa to a mucoid phenotype
during chronic infection which may have significant impacts
on the exposure and expression of surface antigens and is
likely to be an additional challenge in developing effective
vaccines to protect against this pathogen.
There are considerable advances yet to be made both in
our knowledge of the host response and in the development
of an effective vaccine for this difficult pathogen, again
demonstrating that antigen identification is only a fraction of
the process to a successful vaccine. These studies also highlight the limitations of immunoproteomics to predict good
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Table 1.
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Examples of Immunoproteomics Studies to Identify Vaccine Antigens and/or Virulence Factors in Respiratory Pathogenic
Bacteria

Pathogen

#

Antigen(s) of interest

Serum source

Protein fraction

Protective

Comment

Ref

Bd. pertussis

30

Pertactin, serum resistance protein
(BrkA), OmpP, sulphate binding protein
(Sbp)

Immunised children (whole cell
pertussis vaccine)

Total membrane
proteins & extracellular proteins

NA

Observed differences between
mouse and human serum data

[35]

Bd. pertussis

1

Peptidoglycan associated lipoprotein

Immunised mice

Cell lysate

NA

immunodominant antigen

[62]

25

Serum resistance protein, pertactin, HSP60, HSP70,Clp protease, serine protease,
EF-Tu, Glutamyl-tRNA aminotransferase, phosphoenolpyruvate synthase

Bd. pertussis

Immunised mice

Soluble proteins

NA

Comparison of
two vaccine
strains

[34]

Bd. pertussis

11

Serum resistance protein, pertactin, serotype fimbral subunit, HSP-60, HSP-10,
ATP synthase

Immunised mice

Surface proteins

NA

Comparison of
two vaccine
strains

[33]

B. cepacia

18

EF-Tu, pyruvate carboxylase, ATPdependent zinc metalloprotease, tyrosyltRNA synthase, phospholipid glycerol
acyltransferase, ABC efflux pump

Immunised mice

Secreted proteins

NA

B. pseudomallei

12

GroEL, DnaK, PhaP, Ef-Tu, polyribonucleotide nucleotidyltransferase

Immunised rabbit serum

Surface proteins

NA

9 Antigens both
biotinylated and
immunoreactive

[14]

B. thailandensis

16

Ef-Tu, DnaK, AhpC, oxodipate CoA
succinyltransferase, HSP10,

Rabbit from B.
mallei immunised rabbits

Protection

EF-Tu
immunoprotective

[63]

31

F1F0 ATP synthase, EF-Tu, glutamyltRNA synthase, fructose bisphosphatealdolase, GAPDH, pyruvate dehydrogenase, DnaK

Tularemia patients and vaccinated individuals

NA

F. tularensis

F. tularensis

Mouse sera from
Live attenuated
immunised mice

Soluble and
membrane enriched

NA

Lipoprotein L21, L41, L32. Loa22.

Rat infection

Membrane proteins, in vitro
culture and
guinea pig infection

NA

51

PasP protease, zinc dependent aminopeptidase, azurin, OprH, LasB protease,
PrpL protease

CF patient sera

Extracellular

NA

33

TufA (EF-Tu), alcohol dehydrogenase,
DnaK, cysteine synthase, aconitasehydratase, ATP synthase F1, Opa900

Total protein

No serum
bactericidal antibodies
produced

9

Leptospira
interrogans

P. aeruginosa

N. meningitidis

EF-Tu, GroEL, ATP synthase, DNA
gyrase, chitinase family 18 protein, DNA
directed RNA polymerase

Convalescent
patients

[27]

[64]

Comparison of
responses from
successful vaccination and
unsuccessful
vaccination –
examples of
successful vaccination in bold.

[65]

[66]

Compared 2
strains, PA01
and PA14

[51]

[29]
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(Table 1) Contd….

Pathogen

S. pneumoniae

S. pneumoniae

#

Antigen(s) of interest

Serum source

Protein fraction

Protective

17

GlutamyltRNAamidotransferase,GAPDH,
fructose bis-phosphate aldolase, 6PGD

Healthy children and adults
(asymptomatic
carriage)

Surface proteins

4 tested, all
showed
protection

23

Enolase, serine protease, Nacetylglucosamine-6-phosphate
deacetylase, general stress protein,
pneumococcal histidine triad protein D precursor , Zinc metalloprotease

Immunised
rabbits

Secreted proteins

No in vivo
studies

Comment

Ref

[9-11]

All 6 listed immunoreactive proteins found in
all 3 clinical strains
tested.

[13]

# Number of antigens identified.

vaccine antigens. Although flagellin type B protein (FliC)
was identified in an immunoproteomics analysis of extracellular P. aeruginosa proteins using CF patient serum [51],
confirming its potential to produce high antibody titres; neither OprF nor OprI were identified in this study. The authors
attributed the presence of flagellin and other OMPs among
extracellular immunogens to bacterial cell lysis. However,
OprF and OprI would also be expected to be present in a
bacterial lysate. Their lack of detection in this study could
suggest that they were not released from the cell surface,
under the conditions tested, or like certain Bd. pertussis antigens these may not be amenable to detection by immunoproteomics.
CONCLUSIONS
Examples of immunoreactive proteins identified by immunoproteomics in a range of respiratory pathogens are
listed in (Table 1). Many of these are common across several
unrelated bacteria. For example, GroEL (HSP60) and DnaK
(HSP70), are both conserved heat shock proteins and are
highly immunoreactive in several diverse pathogens including Shigella flexineri, Helicobacter pylori and Yersinia entercolitica [52-54]. Immunisation with GroEL, but not DnaK
resulted in 100% protection in mice following Bacillus anthracis challenge [55]. GroEL immunisation was also protective against S. pneumoniae [56]. EF-Tu is another antigen
which is immunoreactive across several pathogens. Interestingly, while it was protective against B. thailandensis, it was
not protective when used in immunisation studies followed
by challenge with N. meningitidis. In addition, it was among
the immunoreactive proteins that were identified with serum
from both successfully and unsuccessfully vaccinated mice
using an attenuated Francisella tularensis vaccine strain,
suggesting that antibodies against EF-Tu are not protective
against this pathogen [65]. EF-Tu has been shown to bind to
host proteins such as fibronectin, mucin and plasminogen
[57-59] and as a result may play a direct role in the microbial
host response for certain pathogens. This may be an important criterion in discerning the most protective antigens
among all those identified in an immunoproteomics study.
Immunoreactogenicity needs to be considered alongside the
potential pathogenicity of any individual protein, as protective vaccine antigens tend to be those that play a role in
pathogenesis. Many immunoreactive proteins identified in

the studies outlined here are metabolic enzymes and would
be considered to have a cytoplasmic localisation within the
cell. The fact that they are immunogenic during infection in
animals and patients, could be due to bacterial cell lysis or
could be due to these enzymes having as yet an undetermined role in bacterial virulence and are worthy of further
study.
In summary, the advances in immunoproteomics have led
to a massive increase in the potential vaccine candidates
which may be useful to protect against difficult to treat bacterial pathogens. While this review has focussed on respiratory pathogens, many immunoreactive antigens have also
been identified using this approach for other bacterial pathogens, e.g. Staphylococcus epidermidis [60], Campylobacter
concisus [61]. As outlined, this potent technology is not
without limitations, but when used with serum from either
colonised or convalescent patients, it is particularly useful as
it allows researchers to identify immunoreactive antigens
that are expressed during human infection. Further thorough
examination of the host immune response, including immunisation studies in a number of carefully selected models,
will help identify which of the immunogenic proteins can be
taken further to human trials. It is likely that multivalent vaccines can be developed by careful selection of immunoreactive antigens identified with immunomic technologies and
when combined with the appropriate adjuvant will increase
our weaponry in the defence against respiratory bacterial
infections.
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